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Abstract 
 
Bortezomib is a first generation proteasome inhibitor used in the treatment of multiple 
myeloma (MM). A few reports have linked bortezomib exposure with the development of 
thrombotic microangiopathy (TMA). We describe a case of biopsy-proven renal thrombotic 
microangiopathy associated with the use of bortezomib in a 51-year-old man with IgG lambda 
MM. To our knowledge, this is the first biopsy-proven case. In addition, re-exposure to 
bortezomib 18 months later was associated with recurrence of TMA. This supports a possible 
causal role of bortezomib. The exact mechanisms remain to be elucidated. 
 
1. Introduction 
 
Thrombotic microangiopathy (TMA) is a rare cause of renal disease in multiple 
myeloma (MM) patients. It is defined by microangiopathic hemolytic anemia, 
thrombocytopenia and organ injury. Pathological features are arteriolar and capillary 
thrombosis with characteristic abnormalities in the endothelium and vessel wall[1]. 
TMA consists of a spectrum of multiple syndromes: thrombotic thrombocytopenic 
purpura (TTP), hemolytic-uremic syndrome (HUS), atypical HUS and drug-induced TMA. 
TMA has been described in MM patients who received the proteasome inhibitor 
bortezomib[2]-[6]. In this report, we describe a case of renal TMA in a MM patient 
associated with exposure to bortezomib, with recurrence after re-exposure.  
 
2. Case presentation 
 
A 51 year-old Caucasian man was found to have acute kidney injury (AKI) three weeks 
after start of bortezomib(1.3 g/m2)- thalidomide(100 mg)- dexamethasone(40 mg) 
(VTD) therapy for newly diagnosed IgG kappa, Durie-Salmon stage IIIa, ISS high risk 
multiple myeloma (MM). He had been diagnosed with monoclonal gammopathy of 
undetermined significance (MGUS) during the investigation of ulcerating acral skin 
lesions 9 years previously. M-protein level at diagnosis of MGUS had been 4.36 g/L. 
Workup for autoimmunity and cryoglobulinemia had been negative and biopsy of the 
skin lesions had shown nonspecific findings. The extent of the skin lesions seemed to 
correlate with the M-protein level. For this reason the patient had been treated with 
rituximab (7 doses of 375 mg/m2) and therapeutic plasma exchange (TPE). Other 
medical history included hypertension and hypothyroidism. His medications were: 
amlodipine 5 mg, aspirin 80 mg, levothyroxine 75 µg and transdermal fentanyl 50 µg/h. 
The patient had been smoking cigarettes for 30 years. The patient had received no other 
nephrotoxic medication and was well hydrated. Blood pressure was 150/83 mmHg. The 
patient's acral ulcers, which had been relatively well controlled with biweekly TPE for 
the last 9 years, had worsened, with development of a livedoid rash and painful edema 
of hands and feet and multiple necrotising ulcers (see figure 1).  
 
Laboratory investigation showed a creatinine elevation from 1.3 mg/dL prior to start of 
VTD therapy to 2.7 mg/dL (see table 1). Figure 2 illustrates the relation between the 
onset of acute kidney injury and the administration of bortezomib. Proteinuria rose 
from 0.6 g/24h before start of therapy to nephrotic range proteinuria, with a maximum 
of 3.2 g/24h 3 months after start of VTD-therapy (considerably later than the rise of 
creatinine had occurred, see figure 3). There was dysmorphic hematuria (>2000 
RBC/µL). Platelet count was 119,000/µL, Hb 7.5 g/dL with schistocyte excess on 
peripheral blood smear and haptoglobin < 0,1 g/L, indicative of micro-angiopathic 
hemolytic anemia. There was hypocomplementemia (C3 0.68 g/L, C3d 5.9%, C4 0.14 
g/L); cryoglobulins were absent, Coombs test, hepatitis B en C serology, ANF and ANCA 
were negative. ADAMTS-13 activity was mildly reduced (34%). Genetic screening for 
complement mutations was negative. Renal sonogram revealed normal size kidneys 
with increased reflectivity of renal parenchyma. Punch biopsy of the livedoid skin rash 
showed nonspecific changes. Renal biopsy showed 7 out of 36 obsolete glomeruli and 
15% chronic tubulo-interstitial damage. One glomerulus had a capillary thrombus, with 
intimal edema of the afferent arteriole. These findings are indicative of a renal TMA 
lesion (see figure 4). There were no arguments for paraprotein associated renal lesions, 
such as cast nephropathy, amyloidosis, light chain deposition disease, 
membranoproliferative glomerulonephritis or cryoglobulinemia. Electron microscopy 
ruled out cryocrystalglobulinemia.  
 
Based on the renal biopsy findings of TMA and the concomitant worsening acral 
ulcerations, TPE was intensified from biweekly to once every two days. Bortezomib was 
stopped after a total of 3 cycles, mainly because of the necrotizing skin ulcers. Kidney 
function partially recovered to a new baseline creatinine of 2.1 mg/dL. Proteinuria 
diminished from 3.2 to 0.8 g/24h over the following months. The patient was then 
started on lenalidomide(15 mg)-dexamethasone(40 mg). This therapy had to be 
stopped after 7 months due to pancytopenia, despite dose reduction. After 8 months of 
watchful waiting there was disease progression with both increase in serum 
paraprotein level and bone lesions on MRI. Based on the good initial hematological 
response to VTD, the patient was restarted on VD (bortezomib and dexametasone). Note 
that at that time, the possible link between TMA and bortezomib was not clear. Baseline 
creatinine before re-exposure to bortezomib was 2.9 mg/dL. Other medications at that 
time included (total daily doses): nifedipine 120 mg, levothyroxine 75 µg, omeprazole 
40 mg, duloxetine 20 mg, amitryptiline 20 mg, calciumcarbonate 1000 mg, 
cholecalciferol 880 E and acetaminophen 4000 mg. Blood pressure was well controlled. 
 
Four weeks later, after 3 doses of bortezomib, the patient presented with a severe 
hypertension (188/102 mmHg), marked increase in serum creatinine (2.9 to 7.5 mg/dL, 
see figure 5), macroscopic hematuria, proteinuria (1.2 to 2.7 g/24h), micro-angiopathic 
hemolytic anemia (Hb of 7.9 g/dL) and severe thrombopenia (14,000/µL). The patient 
was oliguric. He had excruciating pain in his extremities due to a flare up of the chronic 
ulcers. Because of fluid overload, acidemia and hyperkalaemia, hemodialysis had to be 
started. TPE was again intensified to once every two days. After withdrawal of 
bortezomib, there was a gradual recovery. Proteinuria dropped again to 0.6 g/24h. 
Hemodialysis could be stopped after 2 months, with a new baseline creatinine of 3.2 
mg/dL. Kidney function remained stable during 3 months of follow-up. 
 
3. Discussion 
 
We report a case of renal thrombotic microangiopathy (TMA) associated with the use of 
bortezomib in a multiple myeloma (MM) patient. Bortezomib is a first generation 
proteasome inhibitor used in the treatment of MM. TMA has not been reported as a 
drug-related adverse event in CREST[7] and SUMMIT[8], the Phase 2 trials leading to 
bortezomib's approval. Ironically, bortezomib is even used successfully in the treatment 
of TTP (ADAMTS13-deficiency-mediated TMA)[9], by depleting the causative antibodies. 
We identified five other cases of bortezomib-associated TMA in the literature, featuring 
various combinations micro-angiopathic hemolytic anemia and renal TMA. Morita et 
al[2] and Moore and Roomeril[3] described a picture of severe micro-angiopathic 
hemolytic anemia without significant renal insufficiency. Salmenniemi et al.[4], Mehta et 
al.[5] and Chan et al.[6] described the same hematological picture, with renal 
insufficiency. In both cases a renal TMA lesion was suspected, but no kidney biopsy was 
performed. In Salmenniemi's case, a gingival biopsy was consistent with TMA. Ours is 
the first report of a documented renal TMA lesion after bortezomib exposure. 
 
Carfilzomib, a second-generation proteasome inhibitor, has been linked to TMA in MM 
patients as well. Sullivan et al.[10] presented a patient with severe renal insufficiency 
(without biopsy) and thrombocytopenia. Hobeika et al.[11] described a case without 
significant renal insufficiency or thrombocytopenia, but with prominent hypertension 
and proteinuria, in which renal biopsy showed renal TMA and podocytopathy. Finally, 
Lodhi et al.[12] reported a case of MAHA with severe renal insufficiency in which renal 
biopsy showed features of TMA. 
 
In all these reports the temporal relationship between exposure to bortezomib or 
carfilzomib and occurrence of TMA, and the improvement after discontinuation point 
towards proteasome inhibition as a possible cause of TMA. Our case is unique in that we 
documented recurrence of renal TMA after re-exposure to bortezomib 18 months after 
the initial episode. This further supports a causal role for proteasome inhibition in the 
pathogenesis of renal TMA in multiple myeloma patients. 
 
Drug-induced TMA can be caused by idiosyncratic (non-dose-related) immunologic 
reactions or by toxic (dose-related) effects.[13] The former type has been described 
after exposure to quinine[14], quetiapine[15] and gemcitabine[16] and might be 
attributed to endothelial damage by drug-dependent antibodies. The latter type has 
been described for many drugs, including antiplatelet, immunosuppressive, 
chemotherapeutic and anti-angiogenic agents[17]. Multiple reports of renal TMA have 
been described after exposure to bevacizumab. There is accumulating evidence that this 
could be a direct, on-target effect of the drug[18]. Eremina et al.[19] showed that 
survival of glomerular endothelial cells depends on VEGF from podocytes, by using 
conditional gene targeting: mice in which VEGF was selectively deleted from renal 
podocytes developed severe renal TMA. Although bortezomib has no direct effect on 
VEGF or its receptors, it has been shown that bortezomib triggers a dose-dependent 
inhibition of VEGF transcription via NF-κB pathways[20]-[22]. This down regulation of 
VEGF could lead to damage to the glomerular microvasculature.  
 
However, causality is difficult to establish. Hematopoietic stem cell transplantation, a 
known cause of TMA, could have played a role in 4 of the above-mentioned reports[2], 
[4], [11], [12]. Another possible culprit of TMA in MM patients is the paraprotein itself. 
TMA has been described in MM with an anti-ADAMTS-13 paraprotein[23]. In our case, 
each episode of AKI occurred after a rise in paraprotein levels: at diagnosis of MM and at 
disease progression. Moreover, renal function did not resolve completely after 
discontinuation of bortezomib, nor did the MAHA. Interestingly, the necrotising skin 
ulcers, which had started 9 years previously and were likely to be paraprotein-driven as 
they were rituximab and TPE responsive, flared up together with the two episodes of 
AKI. We therefore hypothesize that our patient had a latent vasculopathy - possibly 
paraprotein-induced - which predisposed him to development of TMA - possibly 
provoked by bortezomib-induced VEGF-deficiency. 
 
Treatment of drug-induced TMA is limited to drug avoidance and supportive care[17]. 
Some authors propose TPE[10] TPE is an established therapy for TTP, restoring 
ADAMTS-13 activity by eliminating the causative antibodies. As the pathophysiology of 
drug-induced TMA is different from TTP, TPE is less likely to be beneficial. We 
intensified the on-going TPE therapy in our patient because of the favourable effect on 
his skin lesions. Whether this had a positive effect on the TMA is uncertain. 
  
4. Conclusion 
 
We report a case of renal TMA in a MM patient who is treated with bortezomib. This is 
the sixth case of TMA associated with bortezomib exposure in the literature. To our 
knowledge, this is the first biopsy proven case. In addition we show that re-exposure to 
bortezomib caused recurrence of TMA 18 months later. The possible mechanisms 
remain to be elucidated. 
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Tables: 
 
 t= 0 
(start 
BTZ) 
t= +3w 
(time of renal 
biopsy) 
t= +4 m 
(1 m after stop 
BTZ)  
t= +18 m 
(rechallenge BTZ) 
t= +19 m 
(start dialysis) 
t= + 22 m 
(after stop of 
dialysis) 
Hb (g/dL) 9.2 7.5 9.2 9.8 7.9 8.7 
WBC (x109/L) 2.43 1.37 2.19 2.63 3.07 2.37 
platelets (x109/L) 128 119 77 34 14 42 
schistocytes (/1000 RBC) <3 4-7 <3 <5 40-50 <5 
haptoglobin (g/L) - <0.1 3.08 1.33 <0.1 0.9 
LDH (U/L) 156 218 102 468 419 237 
creatinine (mg/dL) 1.35 2.65 2.04 3.00 7.49 2.89 
ureum (mg/dL) 39 70 33 80 147 97 
proteinuria (g/24h) 1.2 0.6 1.52 1.37 2.69 0.6 
hematuria (RBC/µL) 258 2079 661 - hematuria hematuria 
pyuria (WBC/µL) 14 24 3 - 56 4 
IgG (g/L) 88.2 - 24.3 16 10.7 - 
 
Table 1. Laboratory values 
BTZ: bortezomib; w: weeks; m: months;  - : not available 
 
 
  
Figures: 
 
 
Figure 1. Acral ulcers 
Painful, necrotising ulcers on hands (A) and feet (B). Note the amputation of distal phalanx 4 and 5 of the left hand. 
 
 
 
Figure 2. First episode of AKI 
x-axis: time (weeks); 0= start of first bortezomib administration; y-axis: plasma creatinine (mg/dL) 
VTD: bortezomib-thalidomide-dexamethasone; arrows: bortezomib-administration 
*: time of renal biopsy 
 
 
 
Figure 3. Evolution of proteinuria 
x-axis: time (months); 0= start of first bortezomib administration; y-axis: 24h-proteinuria (g/24h) 
VTD: bortezomib-thalidomide-dexamethasone; Rd: lenalidomide-dexamethasone; VD: bortezomib-dexamethasone 
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Figure 4. Renal biopsy 
Renal biopsy showed 7 out of 36 obsolete glomeruli and 15% chronic tubulo-interstitial damage. Note the capillary thrombus with intimal edema of the afferent 
arteriole (arrow). 
 
 
 
Figure 5. Second episode of AKI 
x-axis: time (weeks); 0= start of bortezomib rechallenge (18 months after first dose); y-axis: plasma creatinine (mg/dL) 
VD: bortezomib-dexamethasone; arrows: bortezomib-administration 
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